June 2020
Volume 61, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2020
Characterization of response to treatment in infants with retinopathy of prematurity in the ROPE-SOS trial in rural India
Author Affiliations & Notes
  • Abdullah Memon
    University of Illinois at Chicago, Illinois, United States
  • Nita Valikodath
    University of Illinois at Chicago, Illinois, United States
  • Emily Cole
    University of Illinois at Chicago, Illinois, United States
  • Tala Al-Khaled
    University of Illinois at Chicago, Illinois, United States
  • Rawan Allozi Rupnow
    University of Illinois at Chicago, Illinois, United States
  • Joelle Hallak
    University of Illinois at Chicago, Illinois, United States
  • J. Peter Campbell
    Oregon Health and Science University, Illinois, United States
  • Michael F. Chiang
    Oregon Health and Science University, Illinois, United States
  • Parag Shah
    Aravind Eye Hospital, India
  • Narendran Venkatapathy
    Aravind Eye Hospital, India
  • Robison Vernon Paul Chan
    University of Illinois at Chicago, Illinois, United States
  • Footnotes
    Commercial Relationships   Abdullah Memon, None; Nita Valikodath, None; Emily Cole, None; Tala Al-Khaled, None; Rawan Rupnow, None; Joelle Hallak, None; J. Peter Campbell, Genentech (F); Michael Chiang, Inteleretina (I), Novartis (C); Parag Shah, None; Narendran Venkatapathy, None; Robison Chan, Alcon (C), Genentech (C), Novartis (C), Phoenix Technology (C), Visunex Medical Systems (S)
  • Footnotes
    Support  On behalf of the Imaging & Informatics in ROP group; K12EY027720, P30EY001792 and R01EY029673 from the National Institutes of Health, National Science Foundation SCH-1622679, National Science Foundation SCH-1622542, National Science Foundation SCH-1622536, and unrestricted departmental funding from Research to Prevent Blindness
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 2196. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Abdullah Memon, Nita Valikodath, Emily Cole, Tala Al-Khaled, Rawan Allozi Rupnow, Joelle Hallak, J. Peter Campbell, Michael F. Chiang, Parag Shah, Narendran Venkatapathy, Robison Vernon Paul Chan; Characterization of response to treatment in infants with retinopathy of prematurity in the ROPE-SOS trial in rural India. Invest. Ophthalmol. Vis. Sci. 2020;61(7):2196.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Retinopathy of prematurity (ROP) is a leading cause of blindness worldwide. The Retinopathy of Prematurity Eradication – Save Our Sight (ROPE-SOS) group is an ROP telemedicine screening program in South India. Previous work from our group evaluated characteristics of infants that received laser treatment vs anti-VEGF injections. The purpose of this preliminary study is to evaluate progression vs regression of ROP in infants with treatment-requiring ROP by treatment type.

Methods : Infants in rural India were screened for ROP by the ROPE-SOS mobile tele-screening team. Presence of ROP, zone, stage, plus disease, APROP, birth weight (BW), and gestational age (GA) were recorded. Infants that required treatment were transported to Aravind Eye Hospital where treatment was administered and documented. Treatment consisted of either anti-vascular endothelial grown factor (anti-VEGF) injection, laser or vitrectomy. Progression or regression of ROP was noted during follow up visits.

Results : A total of 74 patients were treated for ROP with either bevacizumab (n= 40), laser (n= 31), vitrectomy (n=1), or a combination of these treatments (n=2). The average BW was 1315.3 ± 369.9 grams and the average GA was 30.3 ± 3.0 weeks. Out of 74 patients, 64 (86.4%) had regression of ROP, 6 patients (8.2%) had progression of ROP, and 4 patients (5.4%) had stable disease. 40 patients out of 74 were treated with only bevacizumab, and within this group, 36 patients (90%) had regression of ROP, 3 patients (7.5%) had progression of ROP, and 1 patient (2.5%) had stable disease. 31 patients out of 74 were treated with only laser, and in this subset, 22 patients (71.0%) had regression of ROP, 7 patients (22.6%) had progression of ROP, and 2 patients (6.4%) had stable disease.

Conclusions : Over half of the patients in our study were treated with anti-VEGF injections. A majority of patients who were treated with either bevacizumab or laser had regression of ROP.

This is a 2020 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×